Literature DB >> 34848445

Repurposing Metformin for Cancer Treatment: A Great Challenge of a Promising Drug.

Charupong Saengboonmee1,2, Thanachai Sanlung3, Sopit Wongkham4,5.   

Abstract

The safety windows and toxicity of clinically available known drugs allow drug repurposing to be a popular treatment strategy for several diseases, including cancers. Several common drugs, e.g., metformin, statin, and aspirin are on clinical trials for repurposing in oncology treatment. Most of repurposed drugs, however, cannot be used as single agents and some do not exert any clinically significant effects. The limitations and possible biases from observational studies and preclinical models to repurpose these drugs are debatable. In this article, the limitations and probability of using metformin, one of the most repurposed drugs for cancer treatment and in oncological practice, are discussed.
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Cancer; diabetes mellitus; drug repurposing; metformin; review

Mesh:

Substances:

Year:  2021        PMID: 34848445     DOI: 10.21873/anticanres.15410

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Metformin and Cancer, an Ambiguanidous Relationship.

Authors:  Sarah J Skuli; Safwan Alomari; Hallie Gaitsch; A'ishah Bakayoko; Nicolas Skuli; Betty M Tyler
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-19

2.  Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells.

Authors:  Domenica Scordamaglia; Francesca Cirillo; Marianna Talia; Maria Francesca Santolla; Damiano Cosimo Rigiracciolo; Lucia Muglia; Azzurra Zicarelli; Salvatore De Rosis; Francesca Giordano; Anna Maria Miglietta; Ernestina Marianna De Francesco; Veronica Vella; Antonino Belfiore; Rosamaria Lappano; Marcello Maggiolini
Journal:  J Transl Med       Date:  2022-06-07       Impact factor: 8.440

Review 3.  Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses.

Authors:  Pedro Barrios-Bernal; Zyanya Lucia Zatarain-Barrón; Norma Hernández-Pedro; Mario Orozco-Morales; Alejandra Olivera-Ramírez; Federico Ávila-Moreno; Ana Laura Colín-González; Andrés F Cardona; Rafael Rosell; Oscar Arrieta
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-24

4.  Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients.

Authors:  Woo Jin Jung; Sangmi Jang; Won Joon Choi; Jaewon Park; Gwang Hyeon Choi; Eun Sun Jang; Sook-Hyang Jeong; Won Seok Choi; Jae Hwan Lee; Chang Jin Yoon; Jin-Wook Kim
Journal:  Sci Rep       Date:  2022-08-25       Impact factor: 4.996

5.  Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization.

Authors:  Domenico Mallardo; Ester Simeone; Vito Vanella; Maria Grazia Vitale; Marco Palla; Luigi Scarpato; Miriam Paone; Teresa De Cristofaro; Valentina Borzillo; Alessio Cortellini; Francesca Sparano; Sandro Pignata; Francesco Fiore; Corrado Caracò; Piera Maiolino; Antonella Petrillo; Ernesta Cavalcanti; Secondo Lastoria; Paolo Muto; Alfredo Budillon; Sarah Warren; Paolo Antonio Ascierto
Journal:  J Transl Med       Date:  2022-09-30       Impact factor: 8.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.